Clinical Considerations for CDK4/6 Inhibition Beyond Progression

Video content above is prompted by the following:

• Dr. Conlin to Dr. O’Shaughnessy: How do you approach CDK4/6 inhibitors therapy after progression on first-line treatment?
  • Which patients do you consider for continued CDK4/6 inhibition?​
  • Based on the available clinical data, which CDK4/6 inhibitor would you opt for in this setting, and what factors influence your clinical decision-making?
• Dr. O’Shaughnessy to Dr. Conlin: If a patient progresses on 1L CDK4/6 inhibitor plus fulvestrant, do you typically switch to a different CDK4/6 inhibitor or change the endocrine therapy partner or both in the 2L setting? ​